Silk fibroin nanoparticles for celecoxib and curcumin delivery: ROS-scavenging and anti-inflammatory activities in an in vitro model of osteoarthritis.
Comparative StudyHuman subjects
Names both Celecoxib and Curcumin Phytosome in its title.
Supplement × Prescription·Evidence index
PubMed indexes 8 records that name Celecoxib and Curcumin Phytosome together, either in the title or in an interaction, co-administration, or pharmacokinetic context. Each one is listed below with its study design and, where the abstract states one, the authors’ own conclusion, quoted and linked. This page reports that literature. It does not tell you whether to combine them.
Every statement below is attributed to a named, dated, linked source.
This page lists published research relevant to Celecoxib and Curcumin Phytosome. It deliberately does not state whether the combination is safe, whether it interacts, in which direction, at what dose, or how far apart to take them.
Strongest relevance first: papers naming both substances in the title, then human trials and systematic reviews.
Names both Celecoxib and Curcumin Phytosome in its title.
“Curcumin potentiates the growth inhibitory effect of celecoxib by shifting the dose-response curve to the left. The synergistic growth inhibitory effect was mediated through a mechanism that probably involves inhibition of the COX-2 pathway and may involve other non-COX-2 pathways. This synergistic effect is clinically important because it can be achieved in the serum of patients receiving standard anti-inflammatory or antineoplastic dosages of celecoxib.”
Names both Celecoxib and Curcumin Phytosome in its title.
“The results showed that celecoxib (20 µg/ml) induced a significant increase in cytotoxicity, reactive oxygen species (ROS) formation, mitochondria membrane potential (ΔΨm) collapse, lipid peroxidation, oxidative stress and mitochondrial swelling while CuCsSLN and curcumin reverted the above toxic effect of celecoxib.”
Names both Celecoxib and Curcumin Phytosome in its title.
“The detection limit based on three times the standard deviation of the blank was 5.8 ng mL-1 for celecoxib and relative standard deviations (RSD) of 3.6% and 1.8% were obtained for eight replicate determinations of 60 ng mL-1 and 180 ng mL-1 of celecoxib, respectively. The method was applied to the determination of celecoxib in serum samples.”
Names both Celecoxib and Curcumin Phytosome in its title.
“Our findings show the prominent anti-proliferative effects of celecoxib and/or curcumin on MDA-MB-231 cells, providing a rationale for further detailed preclinical and potential clinical studies of this combination for breast cancer therapy. Further, these computed parameters suggested that curcumin possesses a high tendency to act as an adjuvant drug with celecoxib in the treatment of breast cancer.”
Names both Celecoxib and Curcumin Phytosome in its title.
Names both Celecoxib and Curcumin Phytosome in its title.
Names both Celecoxib and Curcumin Phytosome in its title.
“Similar results have been obtained when celecoxib and curcumin were co-administrated at the same time. Overall our data suggest that this natural and synthetic drug combination is detrimental for cell death induction.”
Names both Celecoxib and Curcumin Phytosome in its title.
Search-based evidence indexes have real limits, and it is worth being explicit about them:
NutriStack is a free iPhone app for organising a supplement routine: what you take, when, and what the published record says about it. Its exploratory interaction checker covers Celecoxib, Curcumin Phytosome, and several hundred other substances.
The checker is a research and organisation tool, not a clinical decision aid, and its per-pair assessments are excluded from search until they pass claim-level review.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.